Mobile

A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREA...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005036-24

A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE ALONE

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to compare the efficacy of 6 dose levels of oral CP 690,550 (20 mg once daily [QD] and 15 mg, 10 mg, 5 mg, 3 mg and 1 mg twice daily [BID]), versus placebo, for the treatment of signs and symptoms, administered over 12 weeks, in subjects with active RA on a stable background of MTX who have had an inadequate response to MTX alone.

Critère d'inclusion

  • Rheumatoid Arthritis

Liens